Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Inclusion Criteria:

• Histologically confirmed newly diagnosed ovarian epithelial, fallopian tube, or primary peritoneal carcinoma, including one of the following histologic cell types:

  • Serous adenocarcinoma
  • Endometrioid adenocarcinoma
  • Mucinous adenocarcinoma
  • Undifferentiated carcinoma
  • Clear cell adenocarcinoma
  • Mixed epithelial adenocarcinoma
  • Transitional cell carcinoma
  • Malignant Brenner tumor
  • Adenocarcinoma not otherwise specified
  • Carcinosarcoma
• Stage II-IV disease defined surgically with either optimal (≤ 1 cm) or suboptimal residual disease
• Has undergone initial surgery for diagnosis, staging, and cytoreduction within the past 1-12 weeks

• No current diagnosis of borderline ovarian epithelial tumor (formerly "tumors of low malignant potential") or recurrent invasive ovarian epithelial, primary peritoneal, or fallopian tube cancer treated with surgery only (e.g., stage IA or IB low-grade ovarian epithelial or fallopian tube cancers)

  • Patients with a prior diagnosis of a borderline tumor that was surgically resected and who subsequently developed an unrelated, new invasive ovarian epithelial, primary peritoneal, or fallopian tube cancer are eligible provided they have not received prior chemotherapy for any ovarian tumor

• No prior or synchronous primary endometrial cancer, unless all of the following criteria are met:

  • Disease stage ≤ IB
  • No more than superficial myometrial invasion
  • No vascular or lymphatic invasion
  • No poorly differentiated subtypes, including papillary serous, clear cell, or other FIGO grade 3 lesions
• No history or evidence of primary brain tumor or brain metastases by physical exam
• GOG performance status 0-2
• ANC ≥ 1,500/mm^3 (not induced or supported by granulocyte colony-stimulating factors)
• Platelet count ≥ 100,000/mm^3
• Creatinine ≤ 1.5 times upper limit of normal (ULN)
• Bilirubin ≤ 1.5 times ULN
• SGOT ≤ 2.5 times ULN
• Alkaline phosphatase ≤ 2.5 times ULN
• Albumin ≥ 3.0 g/dL
• PT/INR ≤ 1.5 (or an in-range INR, usually between 2 and 3, if patient is on a stable dose of therapeutic warfarin)
• PTT < 1.5 times ULN
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 3 months after completion of study treatment
• No clinically significant proteinuria (i.e., urine protein:creatinine ratio ≥ 1.0)
• No neuropathy (sensory and motor) > CTCAE grade 1
• No acute hepatitis or active infection requiring parenteral antibiotics

• No serious non-healing wound, ulcer, or bone fracture

  • Patients with granulating incisions healing by secondary intention are eligible provided there is no evidence of fascial dehiscence or infection and the patient undergoes weekly wound examinations
• No abdominal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess within the past 28 days
• No clinical symptoms or signs of GI obstruction and/or requirement for parenteral hydration or nutrition
• No active bleeding or pathologic condition that carries a high risk of bleeding (e.g., known bleeding disorder, coagulopathy, or tumor involving major vessels)

• No clinically significant cardiovascular disease, including any of the following:

  • Uncontrolled hypertension, defined as systolic BP > 150 mm Hg or diastolic BP > 90 mm Hg
  • Myocardial infarction or unstable angina within the past 6 months
  • NYHA class II-IV congestive heart failure
  • Serious cardiac arrhythmia requiring medication
  • Peripheral ischemia ≥ CTCAE grade 2 (at least brief [< 24 hours] episodes of ischemia managed non-surgically and without permanent deficit)
• No cerebrovascular accident, transient ischemic attack, or subarachnoid hemorrhage within the past 6 months
• No seizures not controlled with standard medical therapy or other evidence of CNS disease by physical exam
• No other invasive malignancies within the past 5 years, except for nonmelanoma skin cancer and localized cancer of the breast or head and neck
• No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
• No significant traumatic injury within the past 28 days
• See Disease Characteristics
• No prior cancer treatment that would contraindicate study therapy

• More than 5 years since prior chemotherapy for any abdominal or pelvic tumor

  • Prior adjuvant chemotherapy for localized breast cancer is allowed provided it was completed > 3 years ago AND the patient remains free of recurrent or metastatic disease

• No prior radiotherapy to any portion of the abdominal cavity or pelvis

  • Prior radiotherapy for localized cancer of the breast, head and neck, or skin is allowed provided it was completed > 3 years ago AND the patient remains free of recurrent or metastatic disease
• More than 28 days since prior major surgical procedure or open biopsy
• More than 7 days since prior core biopsy
• No concurrent major surgical procedure